Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Three-year extension study of FTY720 versus mycophenolate mofetil with cyclosporine and corticosteroids in adult de novo kidney transplant recipients
2004-004958-63Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fingolimod, mycophenolate mofetil, cyclosporine and corticosteroids in kidney transplant immunosuppression (3 arms), sponsored by Novartis. Primary endpoints: Biopsy proven acute rejection, Graft loss and 2 more. Started Jun 2005; status: completed.
02
Drugs
fingolimodmycophenolate mofetilcyclosporinecorticosteroids
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on 2004-004958-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004958-63.